Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company focused on pioneering novel cancer therapies. The company specializes in the discovery, development, and commercialization of drugs targeting nuclear export proteins for the treatment of cancer and other significant diseases. Its flagship product, XPOVIO® (selinexor), is a first-in-class, oral exportin 1 (XPO1) inhibitor and is approved in the U.S. for multiple oncology indications. These include combination therapies with Velcade® (bortezomib) and dexamethasone for multiple myeloma, as well as treatments for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Recent achievements highlight the company's commitment to advancing its late-stage clinical pipeline. Notably, Karyopharm has been at the forefront in evaluating selinexor's efficacy in combination therapies for multiple myeloma, endometrial cancer, and myelofibrosis. The company recently reported long-term follow-up data from a Phase 1/3 study on selinexor in combination with ruxolitinib in myelofibrosis patients, showing promising results in spleen volume and symptom reduction.
Financially, Karyopharm reported total revenue of $33.7 million for Q4 2023, with a full-year revenue of $146.0 million. Despite a competitive market, the company managed to maintain steady growth and focused resources on its high-potential pipeline. With a cash position of $192.4 million as of December 31, 2023, Karyopharm is well-positioned to continue its innovative research and development efforts.
Karyopharm's collaborations with global partners, including Antengene, Menarini, Neopharm, and FORUS, have extended the reach of XPOVIO to various international markets such as Europe, China, South Korea, and Israel. This international expansion underscores the global demand for innovative cancer therapies.
For more information, please visit www.karyopharm.com.
Karyopharm Therapeutics (Nasdaq: KPTI) announced promising results from a Phase 1 study on selinexor combined with ruxolitinib in treatment-naïve myelofibrosis patients. At Week 24, the 60mg dose achieved a 92% SVR35 and 78% TSS50 in the efficacy evaluable population, with 79% SVR35 and 58% TSS50 in the intent-to-treat population. The safety profile was generally tolerable, with common adverse effects like nausea and anemia. Karyopharm is planning to initiate a pivotal Phase 3 study in the first half of 2023 to further explore this combination therapy. Investor interest is high, with a webcast featuring key opinion leader Dr. John Mascarenhas discussing the study's implications. These results could potentially transform treatment options for myelofibrosis.
Karyopharm Therapeutics (NASDAQ: KPTI) announces the presentation of updated data from its Phase 1 study on selinexor, combined with ruxolitinib, to treat treatment-naïve myelofibrosis. These findings will be showcased at the AACR Annual Meeting 2023 in Orlando, Florida, on April 18, 2023. The study's poster session will cover 12 and 24-week data across all patients, including the recommended dose. Additionally, Karyopharm will host an investor webcast on the same day at 4:30 p.m. ET, featuring a key opinion leader discussing the therapy's potential and the unmet medical need in this patient population. Selinexor, marketed as XPOVIO, is a pioneering treatment in the field of oncology, having received regulatory approvals in various countries for multiple cancer indications.
Karyopharm Therapeutics (Nasdaq: KPTI) announced on April 3, 2023, the grant of 221,900 restricted stock units (RSUs) to thirteen new employees, effective March 31, 2023. The RSUs will vest over three years, with one-third vesting annually. Additionally, Senior VP Tahira Payne received 60,000 RSUs, vesting at 25% each year for four years. These equity awards comply with the 2022 Inducement Stock Incentive Plan and Nasdaq Listing Rule 5635(c)(4). The vesting of awards is contingent on ongoing employment, with provisions for immediate vesting upon certain terminations of employment.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced that results from its Phase 1 study on selinexor combined with ruxolitinib for treatment-naïve myelofibrosis will be presented at the AACR Annual Meeting 2023. The combination therapy showed potential efficacy, with updates indicating a ≥35% reduction in spleen volume and a ≥50% reduction in symptom scores among 24 patients followed for 24 weeks. Safety data demonstrated the combination was generally well tolerated. An investor webcast is planned to discuss the study results, emphasizing the potential impact of XPO1 inhibition in myelofibrosis treatment.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a leader in cancer therapies, will participate in a fireside chat at the Barclays Global Healthcare Conference on March 15 at 4:35 p.m. ET. The event will feature insights from the company’s senior management team. Investors can access a live webcast and accompanying slides on the company’s Investor website, with a replay available for 90 days post-event. Karyopharm is known for its pioneering SINE compound technology and its lead product, XPOVIO®, which is approved in multiple oncology indications.
FAQ
What is the current stock price of Karyopharm Therapeutics (KPTI)?
What is the market cap of Karyopharm Therapeutics (KPTI)?
What is Karyopharm Therapeutics' main focus?
What is XPOVIO® (selinexor)?
What recent achievements has Karyopharm reported?
Who are Karyopharm's global partners?
What are Karyopharm's financial highlights?
What are the key indications for XPOVIO?
What is the significance of Karyopharm's research on nuclear export proteins?
How does Karyopharm support clinical trials and research?
What are the safety considerations for XPOVIO?
How can I get more information about Karyopharm's products or clinical trials?
